SCHEMBL5879876

SCHEMBL5879876

Cc1ccc(S(=O)(=O)Oc2ccc(F)cc2C=NNC(=O)Cc2cccc(Cl)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.53
ALDH1A1 P00352 8/20 0.53
MAPT P10636 6/20 0.53
KMT2A Q03164 3/20 0.50
HTT P42858 3/20 0.50
MEN1 O00255 2/20 0.50
MAPK1 P28482 2/20 0.46
GAA P10253 1/20 0.45
POLB P06746 2/20 0.45
NPC1 O15118 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SGK1 O00141 1/20 0.43
ANO1 Q5XXA6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879875 1.00 LMNA (0.53) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5880164 0.94 LMNA (0.50) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5880160 0.94 LMNA (0.50) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5879622 0.92 LMNA (0.60) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5879620 0.92 LMNA (0.60) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5880105 0.90 ALDH1A1 (0.59) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5879896 0.90 LMNA (0.43) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL5879892 0.90 LMNA (0.43) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL5880110 0.90 ALDH1A1 (0.59) LMNAALDH1A1MAPTKMT2AHTT
SCHEMBL5880060 0.88 ALDH1A1 (0.47) LMNAALDH1A1MAPTKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 LMNA 4281/4885ALDH1A1 1095/4885MAPT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.